TRAWHealthcare · BiotechnologyThe 2 Wall Street analysts covering Traws Pharma, Inc. hold a median 12-month price target of $1 — +92.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 14 Sept 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Traws Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (94): Smaller than most of the companies we track.
Value (15): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on TRAW, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +92.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Aug 2026 | HC Wainwright & Co. | Reiterates | Neutral | $1.00 |
| 18 June 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 18 June 2026 | HC Wainwright & Co. | Downgrade | Neutral | $1.00 |
| 15 June 2026 | Ladenburg Thalmann | Downgrade | Neutral | — |
| 15 June 2026 | Ladenburg Thalmann | Downgrade | Neutral | — |
| 20 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Dec 2025 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TRAW appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Sept 2026, Traws Pharma, Inc. returned −72.8% against +17.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 70% of US stocks
Cheaper than 40% of US stocks
Cheaper than 20% of US stocks
Cheaper than 62% of US stocks
Higher than 1% of US stocks
Higher than 7% of US stocks
Higher than 30% of US stocks
Higher than 4% of US stocks
Higher than 3% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Traws Pharma, Inc. has a market value of $8.7M and an enterprise value of $3.7M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$21.6M.
Free cash flow in the twelve months to 30 June 2026: −$19.4M.
Trailing P/E: 1.9×; forward P/E: −0.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Traws Pharma, Inc. employs 4 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Traws Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Traws Pharma reported its financial results and business highlights for the quarter ended June 30, 2026, including updates on its lead clinical programs and the April 2026 financing.
Why it matters — This report provides TRAW watchers with the company's latest quarterly financial data and progress on its lead clinical programs and financing.
The 2 Wall Street analysts covering Traws Pharma, Inc. have a median 12-month price target of $1, with estimates ranging from $1 to $1. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Traws Pharma, Inc., 0 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Traws Pharma, Inc. 48 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Sept 2026, Traws Pharma, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +92.7% from the last close, and Ticker Nerd's factor model ranks Traws Pharma, Inc. 48 out of 100 as at 14 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Traws Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TRAW are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $1 over the next 12 months.
Traws Pharma, Inc. returned -72.8% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for respiratory viral diseases and cancer.
The most recent item we track (GlobeNewsWire, 14 Aug 2026): "Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights". Traws Pharma reported its financial results and business highlights for the quarter ended June 30, 2026, including updates on its lead clinical programs and the April 2026 financing.
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for respiratory viral diseases and cancer. Traws Pharma’s current pipeline centers on investigational antiviral and oncology programs, including candidates for influenza, COVID-19, bird flu, and certain cancers. Its respiratory viral disease portfolio is designed to address treatment resistance and unmet medical needs in high-risk infections, while its oncology programs target solid tumors and hematological malignancies. The company’s work spans drug discovery, clinical development, and regulatory planning, with an emphasis on novel mechanisms of action and oral administration. Based in Newtown, Pennsylvania, Traws Pharma operates as a small-cap biotechnology name within the healthcare sector, where it contributes to the advancement of specialized therapies for serious diseases.
CEO Dr. Iain D. Dukes DPHIL, M.A., Ph.D. · 4 employees · United States · https://www.trawspharma.com
